381
Views
10
CrossRef citations to date
0
Altmetric
Short Communications

Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan

, , , , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 13-17 | Accepted 31 May 2019, Published online: 12 Aug 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Nicole Hartwig Trier & Gunnar Houen. (2023) Anti-citrullinated protein antibodies as biomarkers in rheumatoid arthritis. Expert Review of Molecular Diagnostics 0:0, pages 1-17.
Read now

Articles from other publishers (9)

Laura C. Cappelli, George Reed, Dimitrios A. Pappas & Joel M. Kremer. (2023) A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis. Rheumatology and Therapy 10:6, pages 1669-1681.
Crossref
Omar Jabado, Michael A. Maldonado, Michael Schiff, Michael E. Weinblatt, Roy Fleischmann, William H. Robinson, Aiqing He, Vishal Patel, Alex Greenfield, Jasmine Saini, David Galbraith & Sean E. Connolly. (2021) Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. Rheumatology and Therapy 9:2, pages 391-409.
Crossref
Jiaxi Liu, Jinfang Gao, Zewen Wu, Liangyu Mi, Na Li, Yajing Wang, Xinyue Peng, Ke Xu, Fengping Wu & Liyun Zhang. (2022) Anti-citrullinated Protein Antibody Generation, Pathogenesis, Clinical Application, and Prospects. Frontiers in Medicine 8.
Crossref
Zhuqian Wang, Jie Huang, Duoli Xie, Dongyi He, Aiping Lu & Chao Liang. (2021) Toward Overcoming Treatment Failure in Rheumatoid Arthritis. Frontiers in Immunology 12.
Crossref
Shin-ya Kawashiri, Yushiro Endo, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Shuji Nagano, Yoshifumi Tada & Atsushi Kawakami. (2021) Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan. BMC Musculoskeletal Disorders 22:1.
Crossref
Shin-Ya Kawashiri, Yushiro Endo, Ayako Nishino, Momoko Okamoto, Sosuke Tsuji, Ayuko Takatani, Toshimasa Shimizu, Remi Sumiyoshi, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Toshiyuki Aramaki, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Shuji Nagano, Yoshifumi Tada & Atsushi Kawakami. (2021) Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA). Medicine 100:28, pages e26592.
Crossref
Philip J. Mease, Iain B. McInnes, Vibeke Strand, Oliver FitzGerald, Harris A. Ahmad, Yedid Elbez & Subhashis Banerjee. (2020) Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. Rheumatology International 40:7, pages 1021-1028.
Crossref
Valquiria G. Dinis, Vilma T. Viana, Elaine P. Leon, Clóvis A. Silva, Carla G. Saad, Julio C. Moraes, Eloisa S. Bonfa & Ana C. Medeiros-Ribeiro. (2020) Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. Clinical Rheumatology 39:6, pages 1747-1755.
Crossref
Soshi Okazaki, Ryu Watanabe, Hideo Harigae & Hiroshi Fujii. (2020) Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. The Tohoku Journal of Experimental Medicine 250:3, pages 153-159.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.